Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
作者信息
Zhang Zhenyu, Chan Aden Ka-Yin, Ding Xiaojie, Li Yanxi, Zhang Ruiqi, Chen Lingchao, Liu Ying, Wang Yin, Xiong Ji, Ng Ho-Keung, Yao Yu, Zhou Liangfu
机构信息
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China; Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; Neurosurgical Immunology Laboratory of Huashan Hospital, Fudan University, Shanghai, China; Department of Pathology, Basic Medical Science, Fudan University, Shanghai, China; Department of Neuropathology, Huashan Hospital, Fudan University, Shanghai, China.
出版信息
Neuro Oncol. 2017 Jul 1;19(7):1008-1010. doi: 10.1093/neuonc/nox042.
Abstract
摘要
相似文献
1
Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.根据异柠檬酸脱氢酶（IDH）和端粒酶逆转录酶（TERT）启动子突变分类的胶质瘤组在原发性和复发性胶质瘤中保持稳定。
Neuro Oncol. 2017 Jul 1;19(7):1008-1010. doi: 10.1093/neuonc/nox042.
2
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.TERT 启动子突变与 1p/19q 状态无关，对 IDH1/2 突变的成人弥漫性胶质瘤具有有利的预后。
Acta Neuropathol Commun. 2020 Nov 23;8(1):201. doi: 10.1186/s40478-020-01078-2.
3
Clinical implications of molecular analysis in diffuse glioma stratification.分子分析在弥漫性胶质瘤分层中的临床意义。
Brain Tumor Pathol. 2021 Jul;38(3):210-217. doi: 10.1007/s10014-021-00409-y. Epub 2021 Jul 15.
4
[Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].[端粒酶逆转录酶（TERT）与异柠檬酸脱氢酶（IDH）基因联合突变分析在弥漫性浸润性胶质瘤中的预后意义]
Zhonghua Bing Li Xue Za Zhi. 2018 Sep 8;47(9):658-663. doi: 10.3760/cma.j.issn.0529-5807.2018.09.002.
5
Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.基于端粒酶逆转录酶（TERT）启动子和异柠檬酸脱氢酶（IDH）突变的分类可对II/III级胶质瘤的亚型进行表征。
Neuro Oncol. 2016 Aug;18(8):1099-108. doi: 10.1093/neuonc/now021. Epub 2016 Mar 7.
6
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.基于肿瘤中1p/19q、异柠檬酸脱氢酶（IDH）和端粒酶逆转录酶（TERT）启动子突变的胶质瘤分组
N Engl J Med. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10.
7
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.在 IDH 突变型和 IDH 野生型弥漫性胶质瘤中，使用端粒酶启动子突变来标记具有相互临床行为的特定分子亚群。
J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.
8
TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.端粒酶逆转录酶（TERT）启动子突变有助于异柠檬酸脱氢酶（IDH）突变预测世界卫生组织（WHO）二级和三级弥漫性胶质瘤对辅助治疗的不同反应。
Oncotarget. 2015 Sep 22;6(28):24871-83. doi: 10.18632/oncotarget.4549.
9
Molecular categorisation of gliomas.胶质瘤的分子分类
Lancet Oncol. 2015 Jul;16(7):e320. doi: 10.1016/S1470-2045(15)00073-X. Epub 2015 Jun 18.
10
The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas.人类脑胶质瘤中 TERT 启动子突变与 IDH1/2 突变和 1p/19q 缺失的相关性分析。
Medicine (Baltimore). 2022 Jul 22;101(29):e29668. doi: 10.1097/MD.0000000000029668.
引用本文的文献
1
Shape and texture analyses based on conventional MRI for the preoperative prediction of the aggressiveness of pituitary adenomas.基于常规 MRI 的形态和纹理分析对垂体腺瘤侵袭性的术前预测。
Eur Radiol. 2023 May;33(5):3312-3321. doi: 10.1007/s00330-023-09412-7. Epub 2023 Feb 4.
2
Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas.放射治疗延迟 IDH 突变型脑胶质瘤患者的恶性转化并延长其生存时间。
Cancer Biol Med. 2022 Nov 1;19(10):1477-86. doi: 10.20892/j.issn.2095-3941.2022.0472.
3
Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas.小儿 IDH 野生型、H3 野生型半球胶质瘤的分子图谱。
Lab Invest. 2022 Jul;102(7):731-740. doi: 10.1038/s41374-022-00769-9. Epub 2022 Mar 24.
4
TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo.神经祖细胞中的 TERT 启动子 C228T 突变赋予了体内端粒缩短后的生长优势。
Neuro Oncol. 2022 Dec 1;24(12):2063-2075. doi: 10.1093/neuonc/noac080.
5
Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas.TERT 启动子突变在成人弥漫性胶质瘤中的预后意义。
Brain Tumor Pathol. 2022 Jul;39(3):121-129. doi: 10.1007/s10014-021-00424-z. Epub 2022 Jan 31.
6
Comment on Hosmann et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)-Experience at Two Specialized Centers. 2021, , 2540.评论霍斯曼等人的《5-氨基乙酰丙酸荧光是低级别胶质瘤（世界卫生组织二级）手术中的有力预后标志物——两个专业中心的经验》。2021年，，2540。
Cancers (Basel). 2021 Nov 11;13(22):5634. doi: 10.3390/cancers13225634.
7
Identification of magnetic resonance imaging features for the prediction of molecular profiles of newly diagnosed glioblastoma.鉴定磁共振成像特征以预测新诊断胶质母细胞瘤的分子谱。
J Neurooncol. 2021 Aug;154(1):83-92. doi: 10.1007/s11060-021-03801-y. Epub 2021 Jun 30.
8
Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.支链氨基酸转氨酶 1 的富集与多种生物学过程相关，并且与 IDH1 野生型脑胶质瘤患者的不良预后相关。
Aging (Albany NY). 2021 Jan 20;13(3):3645-3660. doi: 10.18632/aging.202328.
本文引用的文献
1
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类：概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
2
TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.端粒酶逆转录酶（TERT）启动子突变有助于异柠檬酸脱氢酶（IDH）突变预测世界卫生组织（WHO）二级和三级弥漫性胶质瘤对辅助治疗的不同反应。
Oncotarget. 2015 Sep 22;6(28):24871-83. doi: 10.18632/oncotarget.4549.
3
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.基于肿瘤中1p/19q、异柠檬酸脱氢酶（IDH）和端粒酶逆转录酶（TERT）启动子突变的胶质瘤分组
N Engl J Med. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10.
4
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.弥漫性低级别胶质瘤的综合、整合基因组分析
N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.
5
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.TERT 启动子突变有助于预测低级别胶质瘤的亚组预后。
Mod Pathol. 2015 Feb;28(2):177-86. doi: 10.1038/modpathol.2014.94. Epub 2014 Aug 1.
6
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.异柠檬酸脱氢酶1（IDH1）、异柠檬酸脱氢酶2（IDH2）以及端粒酶逆转录酶（TERT）启动子的突变可界定成人恶性胶质瘤临床上不同的亚组。
Oncotarget. 2014 Mar 30;5(6):1515-25. doi: 10.18632/oncotarget.1765.
7
Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective.临床试验中胶质瘤的组织病理学诊断的观察者间变异性：临床医生的视角。
Acta Neuropathol. 2010 Sep;120(3):297-304. doi: 10.1007/s00401-010-0725-7. Epub 2010 Jul 20.
8
IDH1 and IDH2 mutations in gliomas.胶质瘤中的异柠檬酸脱氢酶1（IDH1）和异柠檬酸脱氢酶2（IDH2）突变
N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710.
Zotero 插件